MedTrace Logo

A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic Function

NCT03357731 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2020-07-27

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the effects of BMS-986231 on systolic and diastolic parameters in patients with heart failure and low ejection fraction.

Conditions

  • Heart Failure
  • Cardiac Failure
  • Reduced Ventricular Ejection Fraction

Interventions

DRUG

HNO Donor

Infusion

DRUG

Nitroglycerin (NTG)

Infusion

OTHER

Placebo

Infusion

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-30
Primary Completion
2019-05-10
Completion
2019-05-10
FDA Drug
Yes

Countries

  • United States
  • Japan
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03357731 on ClinicalTrials.gov